ZYMERON CORPORATION — Department of Defense SBIR Phase I: DHA231-004
ZYMERON CORPORATION — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $250,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code DHA231-004 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $250,000
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Topic
- DHA231-004
- Solicitation
- 23.1
- NAICS
- —
- Place of performance
- NC
- Period
- 2023-06-21 → 2024-01-29
Description
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients and is characterized by failure of oxygen (O2) and carbon dioxide (CO2) movement (gas exchange) across the alveolar-capillary membrane. Despite its high mortality rate of 30-50%, there are currently no definitive pharmacologic therapies for ARDS. Thus, there is a pressing requirement for novel ARDS treatments that must facilitate immediate O2 delivery to and CO2 removal from alveolar capillaries. Moreover, for sustained ARDS management and ARDS resolution, it has to eliminate inflammation, improve lung compliance and correct perfusion/ventilation mismatch without causing significant side effects. Considering the task of caring for traumatically injured and/or critically ill soldiers on the battlefield, especially in isolated regions, it needs to be easily administered by a minimal number of health care personnel in resource limited settings. Zymeron develops a non-invasive Z-BREATH aerosol therapy for immediate and sustained ARDS management, which can be used in austere environment with minimal clinical staff operation requirements.